Revvity Cxcl1/Gro-(H)Lance Ultra

Revvity The LANCE^® Ultra Human CXCL1/GRO-α Detection Kit is designed for detection and quantitation of human CXCL1 (GRO-α) in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

No-wash steps, no separation steps TR-FRET technology Sensitive detection High reproducibility Faster time-to-results Easy automation 96-well, 384-well, and 1536-well formats

Revvity LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity C-X-C Motif Chemokine 1 (CXCL1) is an 11 kDa chemokine and is part of the intercrine alpha (chemokine CXC) family. The secreted protein is proteolytically processed at the N-terminus and the processed form is usually referred to as GRO-α. CXCL1 is expressed by macrophages, neutrophils and epithelial cells. Its synthesis is induced by a variety of inflammatory mediators such as PDGF, M-CSF, TNFα, LPS, and TLR 4. The major role of CXCL1 is its chemoacttractant activity on neutrophils. CXCL1 plays a role in inflammation and exerts its effects on endothelial cells in an autocrine way. CXCL1 is implicated in spinal cord development, angiogenesis, inflammation, wound healing, and tumorigenesis. CXCL1 is overexpressed in invasive bladder cancer and is secreted by human melanoma cells. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)